← Leaderboards
Gerlinde Wernig
Stanford University
$501,876
Attributed
$501,876
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $167.3K · FY2018–20$200K$150K$100K$50K$0
'18
'19
'20
Funding mix
By agency
NIH$501,876 · 1
By mechanism
K08$501,876 · 1
Top collaborators
No co-investigators on record.
Most similar at Stanford University
Same institution · by research overlap
- Irving Lerner Weissman$56,491,773
- Calvin J Kuo$48,363,495
- Kenan Christopher Garcia$35,612,900
- Hanlee Ji$24,780,644
- Heike Elizabeth Daldrup-Link$23,256,656
Others in their field
Other Emerging Leaders on “Adult”
- Beth Baseler · Leidos Biomedical Research, Inc.$127,607,354
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$93,592,175
- Susan M Landau · University Of California Berkeley$47,252,026
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$42,295,422
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Evan Z Macosko · Broad Institute, Inc.$32,116,761
Research focus
AdultAntibody TherapyAnti-Cd47AntibodiesBaseBiologyBiopsyCancer CellCd47 GeneCell ProliferationCellsCell SurfaceChromatinChronicCicatrixClinical TrialsC-Myc GenesCombined Modality TherapyCurative TreatmentsCytometryDrug EfficacyEatingEffective TherapyEfficacy Testing
Grant awards (3)
Immune Checkpoint Inhibitors as Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis$167,292
K08 · FY2020 · HL · contact PI
Immune Checkpoint Inhibitors as Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis$167,292
K08 · FY2019 · HL · contact PI
Immune Checkpoint Inhibitors as Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis$167,292
K08 · FY2018 · HL · contact PI